A Cautious Note on Thalidomide Usage in Cancer Treatment: Genetic Profiling of the TBX2 Sub-Family Gene Expression is Required

Abstract

Thalidomide is still by excellence the mysterious drug that fascinated, blurred, misled, and changed the scientific community perspectives and policies. It was introduced in the 1950’s as a sedative drug, then shortly withdrawn because of the devastating birth defects that affected tens of thousands throughout more than 40 countries. Back into the market in the mid 1990’s and 2000’s the drug is now being used to treat skin immune-related conditions and some cancers like multiple myeloma. Despite numerous beneficial effects which led to the development of new analogs, its direct mechanisms of action are still elusive. The identification of CRBN and TBX5 as potential direct ligands for this drug have opened the way to better understand its efficiency and its failure.

We hereby review these mechanisms and provide evidence that could explain why thalidomide failed to make it as a drug of choice in lung cancer treatment. Linking the genetic signature of TBX2 subfamily in these tumors to their inability to respond properly to thalidomide raises concerns of worsening lung cancer patients’ health if this drug is utilized.

Key words

thalidomide - TBX2 - clinical trials - lung, cancer

• References

• 1 Vargesson N. Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Res C Embryo Today 2015; 105: 140-156
• 2 Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol 2007; 39: 1489-1499
• 3 Schifrin LG. Thalidomide and beyond: Some recommendations regarding public policies toward the ethical drug industry. Int J Health Serv 1974; 4: 147-155
• 4 Diggle GE. Thalidomide: 40 years on. Int J Clin Pract 2001; 55: 627-631
• 5 Paine MF. Therapeutic disasters that hastened safety testing of new drugs. Clin Pharmacol Ther 2017; 101: 430-434
• 6 von Moos R, Stolz R, Cerny T. et al. Thalidomide: from tragedy to promise. Swiss Med Wkly 2003; 133: 77-87
• 7 Walker SL, Waters MF, Lockwood DN. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev 2007; 78: 197-215
• 8 Nirenberg A. Thalidomide: when everything old is new again. Clin J Oncol Nurs 2001; 5: 15-18
• 9 Mercurio A, Adriani G, Catalano A. et al. A mini-review on thalidomide: chemistry, mechanisms of action, therapeutic potential and anti-angiogenic properties in multiple myeloma. Curr Med Chem 2017; 24: 2736-2744
• 10 Costa P, Fraga LR, Kowalski TW. et al. Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition. Acta Trop 2018; 183: 134-141
• 11 Xiao W, Ernst KH, Palotas K. et al. Microscopic origin of chiral shape induction in achiral crystals. Nat Chem 2016; 8: 326-330
• 12 Knobloch J, Reimann K, Klotz LO. et al. Thalidomide resistance is based on the capacity of the glutathione-dependent antioxidant defense. Mol Pharm 2008; 5: 1138-1144
• 13 Knobloch J, Jungck D, Koch A. The molecular mechanisms of thalidomide teratogenicity and implications for modern medicine. Curr Mol Med 2017; 17: 108-117
• 14 Quach H, Ritchie D, Stewart AK. et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24: 22-32
• 15 Kumar P, Kumar HA, Sundaresan L. et al. Thalidomide remodels developing heart in chick embryo: discovery of a thalidomide mediated hematoma in heart muscle. Naunyn Schmiedebergs Arch Pharmacol 2018; 391: 1093-1105
• 16 Yabu T, Tomimoto H, Taguchi Y. et al. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 2005; 106: 125-134
• 17 Ito T, Ando H, Suzuki T. et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327: 1345-1350
• 18 Fischer ES, Bohm K, Lydeard JR. et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 2014; 512: 49-53
• 19 Ito T, Handa H. Recent topics in IMiDs and cereblon. Rinsho Ketsueki 2017; 58: 2067-2073
• 20 Kronke J, Udeshi ND, Narla A. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014; 343: 301-305
• 21 Bruneau BG, Nemer G, Schmitt JP. et al. A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell 2001; 106: 709-721
• 22 Khalil AA, Sivakumar S, Lucas FAS. et al. TBX2 subfamily suppression in lung cancer pathogenesis: a high-potential marker for early detection. Oncotarget 2017; 8: 68230-68241
• 23 Ludtke TH, Farin HF, Rudat C. et al. Tbx2 controls lung growth by direct repression of the cell cycle inhibitor genes Cdkn1a and Cdkn1b. PLoS Genet 2013; 9: e1003189
• 24 Ludtke TH, Rudat C, Wojahn I. et al. Tbx2 and Tbx3 act downstream of shh to maintain canonical wnt signaling during branching morphogenesis of the murine lung. Dev Cell 2016; 39: 239-253
• 25 Cebra-Thomas JA, Bromer J, Gardner R. et al. T-box gene products are required for mesenchymal induction of epithelial branching in the embryonic mouse lung. Dev Dyn 2003; 226: 82-90
• 26 Arora R, Metzger RJ, Papaioannou VE. Multiple roles and interactions of Tbx4 and Tbx5 in development of the respiratory system. PLoS Genet 2012; 8: e1002866
• 27 Khalil A, Dekmak B, Boulos F. et al. Transcriptomic alterations in lung adenocarcinoma unveil new mechanisms targeted by the tbx2 subfamily of tumor suppressor genes. Front Oncol 2018; 8: 482
• 28 Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol 2016; 893: 1-19
• 29 Swanton C, Govindan R. Clinical Implications of Genomic Discoveries in Lung Cancer. N Engl J Med 2016; 374: 1864-1873
• 30 Reck M, Gatzemeier U. Targeted therapies: Thalidomide in lung cancer therapy-what have we learned?. Nat Rev Clin Oncol 2010; 7: 134-135
• 31 Jazieh AR, Komrokji R, Gupta A. et al. Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer. Cancer Invest 2009; 27: 932-936
• 32 Hoang T, Dahlberg SE, Schiller JH. et al. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: The ECOG 3598 study. J Clin Oncol 2012; 30: 616-622
• 33 Khalil A, Tanos R, El-Hachem N, Kurban M, Bouvagnet P, Bitar F, Nemer G (2017). A HAND to TBX5 explains the link between thalidomide and cardiac disease. Scientific Reports https://doi.org/10.1038/s41598-017-01641-3